Biocardia (BCDA) Fundamental Analysis: Revenue, Earnings & Valuation

3.28 / 10

Netural

Fundamental assessment rates BCDA at 3.3/10, indicating weak fundamentals. Profit‑to‑Market (+0.405) and Inventory turnover (47.57) are positive, while Asset‑MV (‑0.48) and Revenue‑MV (‑0.28) lag. Cash‑MV is slightly negative, Gross margin modest (36.9%), and Income‑tax ratio adverse (‑5.52%).

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score1/3

Weight16.33%

1M Return5.44%

Inventory turnover ratio

Value47.57

Score3/3

Weight19.82%

1M Return6.65%

Gross profit margin (%)

Value36.91

Score1/3

Weight0.77%

1M Return0.36%

Profit-MV

Value0.41

Score2/3

Weight18.64%

1M Return6.36%

Income tax / Total profit (%)

Value-5.52

Score1/3

Weight0.46%

1M Return0.21%

Current assets turnover ratio

Value0.00

Score2/3

Weight4.28%

1M Return1.91%

Fixed assets turnover ratio

Value0.00

Score3/3

Weight3.95%

1M Return1.76%

Cost of sales ratio (%)

Value70.30

Score3/3

Weight9.85%

1M Return4.08%

Asset-MV

Value-0.48

Score0/3

Weight7.65%

1M Return2.73%

Cash-MV

Value-0.09

Score2/3

Weight18.26%

1M Return6.19%

Is BCDA fundamentally strong?

BCDA scores 3.28/10 on fundamentals and holds a Fair valuation at present. Backed by its -950.12% ROE, 0.00% net margin, -1.50 P/E ratio, 4.87 P/B ratio, and 57.59% earnings growth, these metrics solidify its Netural investment rating.